Press Release - BIVDA IVD Market Audit Results Show COVID-19 Impact
BIVDA Press Release –
For Immediate Release
BIVDA IVD Market Audit Results Show COVID-19 Impact
- Report shows substantial impact of COVID-19 pandemic on other diagnostic tests
- Some diagnostic revenues down by as much as 90%
- COVID-19 revenues skyrocket
The BIVDA Market Audit Report for the first half of 2020 has been published to participants. Twenty seven companies submitted revenue data which has been consolidated into a detailed report on the market size and growth, from totals down to assay level. For the first time Thermofisher Scientific have submitted data for their Microbiology products, further enhancing the coverage of the market which exceeds 95% of the total IVD market excluding Glucose self-tests.
The results show a substantial impact of the COVID pandemic and subsequent ‘lockdown’ period on diagnostic tests performed. Although the total market grew by 2.5%, revenues from General Chemistry, Hormones and Tumour Marker tests were reduced by 10 to 15% in the period (and this impact reflects only 3 months of ‘lockdown’ from the half year). Some test revenues were reduced by over 90%, while others increased by as much or more, and revenues from Coronavirus testing became one of the largest categories from negligible levels in 2019.
The BIVDA Market Audit is the most accurate and reliable source of data on the UK IVD market available by far, and participation is open to any UK IVD supplier at no cost if a member of BIVDA. Help in data submission, analysis and interpretation is available from BIVDA, and there is now also a website which allows access to data and generation of customised reports for participants.
For more information contact John Bagshaw, BIVDA Board Member, at JAB Associates.